SSRI-Induced Sex Dysfunction Unameliorated.
The adverse effects of selective serotonin reuptake inhibitors (SSRIs) on sexual function are well documented and are thought to be mediated through serotonin receptors, although the mechanisms are not yet understood, said Dr. Michelson of Eli Lilly Pharmaceuticals in Indianapolis.
Concomitant therapy with agents that affect serotonin receptors or potentiate dopamine activity has been proposed, and both buspirone and amantadine have proven effective in uncontrolled case studies.
Buspirone has 5-HT agonist properties, and amantadine is believed to increase dopamine activity, he said in a poster presentation at the meeting.
He assessed the two agents in a double-blind study of 61 women taking the SSRI fluoxetine. Nineteen of the women were randomly assigned to concomitant amantadine, 21 to buspirone, and 21 to placebo for 8 weeks.
The mean age of the subjects was 39 years. Fifty-four (89%) were taking fluoxetine for depression, and the remainder were receiving the SSRI to treat anxiety, obsessive-compulsive disorder, or PMS.
All the subjects reported at least mildly impaired sexual function while taking fluoxetine, specifically citing impairment of vaginal lubrication and an inability to achieve orgasm.
Neither buspirone nor amantadine improved sexual function better than placebo.
Interestingly the addition of amantadine to fluoxetine therapy did improve subjects' mood and energy level.
|Printer friendly Cite/link Email Feedback|
|Author:||Moon, Mary Ann|
|Publication:||OB GYN News|
|Article Type:||Brief Article|
|Date:||Oct 1, 1999|
|Previous Article:||Maternal Hypothyroidism Can Affect Child's IQ.|
|Next Article:||The Best Teacher.|